A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment
Brittany Vasae Burdick, Bryon Adinoff
The American Journal of Drug and Alcohol Abuse August 22, 2013 DOI: 10.3109/00952990.2013.811513 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Proposed clinical trial Peer reviewed |
|---|---|
| Population | Prescription opioid abusers |
| Interventions | Psilocybin Holotropic Breathwork Niacin |
| Topics | Addiction Cannabis Psilocybin |
| Keywords | Hallucinogen Drug Abstinence Population Pharmacology |
| Key findings | No clinical comparisons of drug-induced and non-drug-induced altered states for addiction treatment have been conducted, and a trial is proposed to evaluate abstinence outcomes in prescription opioid abusers. |
Abstract
Current treatments for addiction are frequently ineffective. Hallucinogenic therapy has been indicated as helpful for a range of substance use disorders, yet this approach remains understudied and publicly unavailable. It is nonetheless a promising treatment, which has significant, long-term beneficial effects with single doses and a profile characterized by general safety, low toxicity, and non-addictiveness. However, pharmacological interventions, such as hallucinogens, should not be offered if the same effects (e.g. psychological insights/mystical experiences) and outcomes (e.g. decreased drug use) could be achieved absent pharmacological intervention. To date, there have been no clinical comparisons of drug-induced altered states with non-drug-induced states for addiction treatment. We propose and then outline a clinical trial to address this gap in knowledge. The proposed design would evaluate abstinence outcomes in a population of prescription opioid abusers after exposure to one of three conditions: a drug-induced altered state using psilocybin, a non-drug-induced altered state via hyperventilation (Holotropic Breathwork), and an active placebo with niacin. The outcomes of such a study would reveal important differences in therapeutic potential by discriminating hallucinogen-dependent effects from those psychological effects resulting from altered states.
Comparable studies
Other non-randomized and open-label trials on addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Psychiatrically healthy nicotine-dependent smokers | 2014 | Open-label pilot study | n = 15 |
| Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction Smokers | 2015 | Open-label pilot study | n = 15 |
| Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Alcoholic patients | 1997 | Controlled clinical trial | n = 211 |
| First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Patients with alcohol use disorder (AUD) following community alcohol detoxification | 2021 | Open-label safety and tolerability proof-of-concept study | n = 14 |
| The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions Participants in a psilocybin-assisted treatment study for alcohol dependence | 2018 | Open-label pilot (proof-of-concept) study with qualitative content analysis | n = 17 |
Citations in the library
Cited by 11
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Therapeutic Advances in Psychopharmacology March 18, 2016
- An online survey of tobacco smoking cessation associated with naturalistic psychedelic use Journal of Psychopharmacology January 18, 2017
- Psilocybin for treating substance use disorders? Expert Review of Neurotherapeutics August 10, 2016
- Motives for the use of serotonergic psychedelics: A systematic review. Drug and Alcohol Review September 1, 2022
and 6 more in the library
Cites 40
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 35 more in the library